Corbus starts TEMPO-1. Corbus Pharmaceuticals stock has 8 Buy ratings

Published on 10/01/2026 at 09:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TEMPO-1 is designed for 250 patients with CRB-701 on September 29, 2026. Corbus Pharmaceuticals stock has 8 Buy ratings and 2 Sells from ten analysts.

CRBP, US21833E1038, Illustration mit AI erstellt.

Corbus Pharmaceuticals (ISIN US21833E1038) dosed the first patient in its 250-patient TEMPO-1 registrational study of CRB-701 on September 29, 2026, according to Corbus Pharmaceuticals. The study evaluates CRB-701 in second-line and later oropharyngeal cancer, while MarketBeat reported on September 30, 2026, that eight of ten analysts rated Corbus Pharmaceuticals stock a Buy and two rated it a Sell.

TEMPO-1 sets a 250-patient test

The randomized study compares CRB-701 with investigator-selected capecitabine, cetuximab or docetaxel. Its primary endpoint is objective response rate, with overall survival intended to support a potential conversion to full approval, according to the September 29, 2026 company release.

The earlier clinical signal gives the trial a measurable benchmark. In patients receiving the 3.6 mg/kg dose, CRB-701 produced a confirmed objective response rate of 42.90 percent, a median response duration of 6.30 months and median progression-free survival of 5.60 months, the company said on September 29, 2026.

Analyst support meets financial pressure

MarketBeat's September 30, 2026 consensus summary puts the average 12-month price target at USD 41.00, while HC Wainwright maintained a Buy rating and a USD 35.00 target in a September 14, 2026 research note cited by the outlet. The breadth of the ratings contrasts with the latest reported earnings performance.

For the second quarter of 2026, Corbus reported a diluted loss of USD 1.81 per share, compared with a consensus loss of USD 1.26 per share, a USD 0.55 wider loss than expected, according to MarketBeat. That gap makes clinical execution important because the company remains in development rather than commercial scale.

Market value remains below yearly high

Corbus Pharmaceuticals had a market capitalization of USD 126.4 million as of September 30, 2026. Its 52-week range was USD 6.33 to USD 20.56 on the same date, placing the company in a valuation profile still shaped by trial milestones and financing risk.